JO
AVBP icon

John Overdeck’s ArriVent BioPharma AVBP Stock Holding History

John Overdeck’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
57,804
+9,122
+19% +$269K ﹤0.01% 2996
2026
Q1 		$1.12M Sell
48,682
-28,797
-37% -$650K ﹤0.01% 3175
2025
Q4 		$1.56M Sell
77,479
-14,239
-16% -$296K ﹤0.01% 2624
2025
Q3 		$1.69M Buy
+91,718
New +$1.8M ﹤0.01% 2238
2025
Q2 		– Sell
-41,381
Closed -$765K – 3608
2025
Q1 		$765K Buy
+41,381
New +$1.01M ﹤0.01% 2323

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's AVBP Position: Q2 2026 in Review

John Overdeck increased its ArriVent BioPharma (AVBP) stake by 19% in Q2 2026, buying an estimated $269K and bringing the position to 57,804 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

John Overdeck first reported a position in AVBP in Q1 2025 and has held it in 5 quarters since. 156 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • John Overdeck held 57,804 shares of ArriVent BioPharma worth $2.01M as of Q2 2026.
  • John Overdeck bought 9,122 ArriVent BioPharma shares in Q2 2026, an estimated $269K.
  • ArriVent BioPharma made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2996 holding.
  • John Overdeck first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 5 quarters since.
  • 156 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.